tradingkey.logo
tradingkey.logo
Search

Maat Pharma Announces Xervyteg's Phase 3 Dedicated Trial Launch In U.S Is Expected In 2026

ReutersJun 19, 2025 5:06 PM
facebooktwitterlinkedin

- Maat Pharma SA MAAT.PA:

  • MAAT PHARMA : AS PART OF A STRATEGIC FOCUS ON XERVYTEG'S REGISTRATION ACTIVITIES IN EUROPE, PHASE 3 DEDICATED TRIAL LAUNCH IN U.S IS EXPECTED IN 2026

  • MAAT PHARMA: EMA MARKETING AUTHORIZATION APPLICATION OF XERVYTEG COULD BE EXPECTED IN H2 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI